Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B. Lv S, et al. Among authors: sadones j. Int J Oncol. 2012 Sep;41(3):1029-35. doi: 10.3892/ijo.2012.1539. Epub 2012 Jun 29. Int J Oncol. 2012. PMID: 22752145 Clinical Trial.
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, In't Veld P, Michotte A, De Greve J. Neyns B, et al. Among authors: sadones j. Ann Oncol. 2009 Sep;20(9):1596-1603. doi: 10.1093/annonc/mdp032. Epub 2009 Jun 2. Ann Oncol. 2009. PMID: 19491283 Free article. Clinical Trial.
Phase II study of sunitinib malate in patients with recurrent high-grade glioma.
Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, De Greve J. Neyns B, et al. Among authors: sadones j. J Neurooncol. 2011 Jul;103(3):491-501. doi: 10.1007/s11060-010-0402-7. Epub 2010 Sep 25. J Neurooncol. 2011. PMID: 20872043 Clinical Trial.
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B. Sadones J, et al. Eur J Cancer. 2009 Jan;45(1):146-53. doi: 10.1016/j.ejca.2008.09.002. Epub 2008 Oct 20. Eur J Cancer. 2009. PMID: 18945611
11 results